Ameriprise’s Guardant Health GH Stock Holding History

Ameriprise’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.3M	Buy	+46,500	New	+$4.67M	﹤0.01%	2537

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's GH Position: Q1 2026 in Review

Ameriprise increased its Guardant Health (GH) stake by 86% in Q1 2026, buying an estimated $65.5M and bringing the position to 1,414,886 shares worth $131M. The position accounts for 0.03% of the portfolio, ranked #477.

Ameriprise first reported a position in GH in Q4 2018 and has held it in 28 quarters since. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Ameriprise held 1,414,886 shares of Guardant Health worth $131M as of Q1 2026.
Ameriprise bought 652,291 Guardant Health shares in Q1 2026, an estimated $65.5M.
Guardant Health made up 0.03% of Ameriprise's portfolio in Q1 2026, its #477 holding.
Ameriprise first reported a position in Guardant Health in Q4 2018 and has held it in 28 quarters since.
481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.